Treponema pallidum - Syphilis

Diagnosis

Indications for Testing

  • Suspicion of syphilis (classic lesions, known exposure, high-risk behaviors)
    • Concurrent STI testing

Laboratory Testing

  • Cannot be cultured in vitro
  • Darkfield exam only if chancre (primary) or condylomata lata (secondary) present
  • Nontreponemal tests – inexpensive and rapid; require treponemal-based confirmation due to modest specificity
    • Rapid plasma reagin (RPR) – if reactive, order titers
    • Venereal disease research laboratory (VDRL) test may be used first but has higher false-positive rate
  • Treponemal tests used for confirmation of positive nontreponemal test
    • Microhemagglutination or indirect hemagglutination assay for antibodies to T. pallidum (MHA-TP, TP-PA)
    • Fluorescent treponemal antibody absorption assay (FTA-Abs) – higher rates of false positives than TP-PA
    • IgM antibody detection by enzyme-linked immunosorbent assay (ELISA)
    • IgG antibodies by immunoblot
  • Neurosyphilis
    • In suspected cases, order VDRL on cerebrospinal fluid (CSF) with concurrent RPR serum
    • If RPR is negative and a high index of suspicion for neurosyphilis remains, perform FTA-Abs on serum
      • Some patients have non-reactive nontreponemal tests in late neurosyphilis
    • CNS is usually the affected site in an HIV patient
  • For further testing recommendations, see the Syphilis Testing Algorithm

Differential Diagnosis

Screening

  • All pregnant females should be screened at initial prenatal visit using VDRL or RPR
    • Follow positive results with FTA-Abs or TP-PA testing (USPSTF, ACOG, CDC, AAFP recommendations)
    • Screening recommendations for pregnant women

      Screening Recommendations for Pregnant Women

      STI

      USPSTF

      CDC

      AAFP

      ACOG

      Chlamydia

      Screen women <25 years and others at increased risk*

      Screen all sexually active females ≤25 years and those >25 who are at risk**

      Screen women ≤25 years and others at increased risk*

      Screen women at increased risk***

      Gonorrhea

      Screen women <25 years and others at increased risk*

      Screen women at increased risk**

      Screen women at increased risk*

      Screen women at increased risk***

      Syphilis

      Screen all

      Screen all

      Screen all

      Screen all

      HIV

      Screen all

      Screen all

      Screen all

      Screen all

      Hepatitis B

      Screen all

      Screen all

      Screen all

      Screen all

      Hepatitis C

      No specific recommendation

      Screen women at increased risk**

      No specific recommendation

      Screen women at increased risk***

      HSV

      Do not screen asymptomatic patients

      No specific recommendation

      Do not screen general population

      No specific recommendation

      HPV

      No specific recommendation

      No specific recommendation

      No specific recommendation

      No specific recommendation

      Bacterial vaginosisDo not screen for low-risk patients; insufficient evidence to recommend screening in patients at high risk for preterm deliveryNo specific recommendationDo not screen for low-risk patients; insufficient evidence to recommend screening in patients at high risk for preterm deliveryNo specific recommendation

      STI = sexually transmitted infection; USPSTF = U.S. Preventive Services Task Force; CDC = Centers for Disease Control and Prevention; AAFP = American Academy of Family Physicians; ACOG = American College of Obstetricians and Gynecologists; HIV = human immunodeficiency virus; HSV = herpes simplex virus; HPV = human papillomavirus; Pap = Papanicolaou

      * At risk = new or multiple partners; diagnosis of gonorrhea or chlamydia with last 12 months; those not consistently using barrier methods; those having sex under the influence of drugs

      ** Increased risk = defined as <25 years with inconsistent condom use; history of other STIs; multiple sex partners or drug use

      *** High-risk factors = history of multiple sexual partners or a sexual partner with multiple contacts; sexual contact with individuals with a culture-proven STI; history of repeated episodes of STIs; attendance at clinics for STIs

  • Screen females at risk
    • Screening recommendations for sexually active nonpregnant women

      Screening Recommendations for Sexually Active Nonpregnant Women

      STI

      USPSTF

      CDC

      AAFP

      ACOG

      Chlamydia

      Yearly screening – screen women <25 years and others at increased risk*

      Do not screen women >25 years and not at high risk

      Screen women ≤25 years and others at increased risk***

      Screen women ≤25 years and others at increased risk*

      Screen women ≤25 years and others at increased risk****

      Gonorrhea

      Screen women <25 years and others at increased risk*

      No recommendation for or against screening women not at risk and >25 years

      Screen women at increased risk***

      Do not screen general population

      Screen women <25 years and others at increased risk*

      Screen adolescents and others at increased risk****

      Syphilis

      Screen women at increased risk**

      Screen women exposed to syphilis

      Screen women at increased risk*

      Screen women at increased risk****

      HIV

      Screen women at increased risk*

      Screen all patients 13-64 years regardless of risk factors

      Screen women at increased risk*

      Screen women at increased risk****

      Hepatitis B

      Do not screen general population

      Provide prevaccination screening for women at increased risk***

      Do not screen general population

      No specific recommendation

      Hepatitis C

      Do not screen general population; insufficient evidence to recommend for or against screening women at increased risk

      Screen women at increased risk***

      Do not screen general population

      Do not screen general population; insufficient evidence to recommend for or against screening women at increased risk*

      Screen women at increased risk****

      HSV

      Do not screen asymptomatic patients

      Do not screen general population

      Do not screen general population

      Screen if sexual partner has HSV

      HPV

      Insufficient evidence to use as primary screening test for cervical cancer

      Do not screen for subclinical infection

      Insufficient evidence to use as primary screening test for cervical cancer

      Testing with a Pap smear is an option for women >30 years

      Bacterial vaginosisDo not screenNo recommendationNo specific recommendationsNo specific recommendations

      STI = sexually transmitted infection; USPSTF = U.S. Preventive Services Task Force; CDC = Centers for Disease Control and Prevention; AAFP = American Academy of Family Physicians; ACOG = American College of Obstetricians and Gynecologists; HIV = human immunodeficiency virus; HSV = herpes simplex virus; HPV = human papillomavirus; Pap = Papanicolaou

      * At risk = new or multiple partners; diagnosis of gonorrhea or chlamydia within the last 12 months; those not consistently using barrier methods; those having sex under the influence of drugs

      ** Commercial sex workers; persons who exchange drugs for sex; incarceration in adult correctional facility; multiple sex partners

      *** Increased risk defined as <25 years with inconsistent condom use; history of other STIs; multiple sex partners or drug use

      **** High-risk factors = history of multiple sexual partners or a sexual partner with multiple contacts; sexual contact with individuals with a culture-proven STI; history of repeated episodes of STIs; attendance at clinics for STIs

  • Screen exposed males
  • Patient with newly diagnosed HIV should have syphilis testing, and patient with newly diagnosed syphilis should have HIV testing
  • If patient has a negative test but continues to engage in risk behavior, retest in 3-12 months

Monitoring

  • Treatment follow-up
    • Nontreponemal tests  measure IgM and IgG antibodies; best for monitoring treatment or for testing for reinfection 
      • Positive titers are used to follow response to therapy for infected patients
      • Rapid plasma reagin (RPR) for serum
      • Venereal disease research laboratory (VDRL) for spinal fluid
    • In CNS disease – CSF titers with VDRL 
      • Titers should decrease with effective treatment

Clinical Background

Treponema pallidum subspecies pallidum is the causative agent of syphilis, a sexually transmitted infection (STI).

Epidemiology

  • Incidence
    • 2-5/100,000
    • Varies by region
    • Incidence has increased in last 5-10 years
  • Age – peaks in teens to late 20s
  • Transmission    
    • Sexual contact
    • Maternal vertical transmission

Organism

  • T. pallidum subspecies pallidum is a member of the Spirochaetales family that causes syphilis and is distinct from the subspecies causing yaws (T. pallidum subspecies pertenue), pinta (T. pallidum subspecies carateum) and endemic syphilis (T. pallidum subspecies endemicum)
  • The Spirochaetales family also includes the following

Risk Factors for Syphilis

  • Early age at onset of sexual activity
  • HIV infection
  • Gonorrhea infection
  • Multiple sex partners
  • Non-Caucasian race
  • Non-use of barrier methods of birth control
  • Previous history of STI

Clinical Presentation

  • Primary syphilis
    • Incubation – 2-3 weeks
    • Painless chancre at site of inoculation – may persist 4-6 weeks
    • Local nontender adenopathy is frequent
    Secondary syphilis
    • Incubation – 6-12 weeks
    • Two types
      • Latent and early latent <1 year infection
      • Late latent ≥1 year infection
    • Diffuse lymphadenopathy
    • Mucocutaneous lesions (condyloma lata) – coalescence in genital regions
    • Macular skin rash (frequently involves palms and soles)
    • Widespread syphilitic vasculitis (~10% of cases)
      • Meningitis (rare)
      • Hepatitis
      • Nephritis
      • Iritis
      • Cranial nerve involvement (most commonly, eighth nerve deafness)
    Tertiary (late) syphilis
    • Incubation – 5-15 years
    • 15-40% of untreated patients develop disease
    • Cardiovascular – aortitis, aneurysm, aortic valvular incompetence
    • Gummatous syphilis – granulomatous, nodular lesions in organs (most commonly skin and bones)
    • Neurologic – general paresis, tabes dorsalis
    Congenital syphilis
    • Can occur during all stages of maternal syphilis – usually in first 2 years of infection
      • One-third of babies born without infection
      • One-third born with congenital syphilis
      • One-third result in miscarriage or stillbirth
    • Typed according to age at diagnosis
      • Early (<2 years, untreated)
        • Snuffles
        • Rash
        • Condyloma lata
        • Bone changes
        • Hepatosplenomegaly
        • Jaundice
        • Anemia
      • Late (>2 years, untreated)
        • Eighth-nerve deafness
        • Arthropathy (Clutton joints)
        • Neurosyphilis
        • Keratitis
      • Residual stigmata
        • Hutchinson teeth
        • Mulberry molars
        • Saddle nose
        • Saber shin
        • Rhagades scars
    Central nervous system (CNS) manifestations
    • May occur at any stage
    • Symptomatic forms
      • Meningeal syphilis (usually <1 year after infection)
        • Involves the brain or spinal cord
        • Symptoms include headache, stiff neck
      • Meningovascular syphilis (usually 5-10 years after infection)
        • Inflammation of pia and arachnoid, with focal arteritis
        • Stroke syndrome involving middle cerebral artery is common in young adults
      • Parenchymatous (late syphilis)
        • General PARESIS (acronym for Personality, Affect; Reflexes, Eye [Argyll Robertson pupil], Sensorium, Intellect, Speech)
        • Tabes dorsalis – demyelination of posterior columns, dorsal roots and dorsal root ganglia
          • Results in weakness, paresthesias, ataxia, dementia, personality changes, decreased reflexes
          • Characterized by wide-based gait and bladder symptoms
          • Optic atrophy (Argyll Robertson pupil) frequently associated with tabes dorsalis
        • Charcot joints – trophic joint degeneration
    • May also be asymptomatic
    Coinfection with HIV
    • Primary syphilis – multiple, large, painful ulcers
    • Secondary syphilis – genital ulcers more common
    • Tertiary syphilis – possibly more rapid progression to neurosyphilis

Treatment

  • All stages of neurosyphilis require treatment to prevent disease progression and sequelae
  • Jarisch-Herxheimer reaction sometimes follows initial syphilis treatment
    • Fever/chills
    • Headache
    • Tachypnea
    • Tachycardia
    • Usually lasts <24 hours
    • Supportive care only
  • Intrauterine treatment <16 weeks into pregnancy prevents fetal damage

Indications for Laboratory Testing

  • Tests generally appear in the order most useful for common clinical situations
  • Click on number for test-specific information in the ARUP Laboratory Test Directory
Test Name and Number Recommended Use Limitations Follow Up
Treponema pallidum (Rapid Plasma Reagin) with Reflex to Titer 0050471
Method: Semi-Quantitative Charcoal Agglutination

Initial screening test for syphilis

Follow treatment response

False positives may be caused by HIV, herpes simplex virus (HSV), malaria, intravenous drug use (IVDU), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), pregnancy, leprosy, endemic treponematoses

 
Treponema pallidum (VDRL), Serum with Reflex to Titer 0093093
Method: Semi-Quantitative Flocculation

Alternative initial screening test for syphilis

Use rapid plasma reagin (RPR) preferentially to decrease false-positive rate

False positives may be caused by HIV, HSV, malaria, IVDU, SLE, RA, pregnancy, leprosy, endemic treponematoses

 
Treponema pallidum Antibody by TP-PA 0050777
Method: Semi-Quantitative Particle Agglutination

Confirm reactive screening nontreponemal test in suspected syphilis

Resolve inconclusive FTA-Abs results

Cannot differentiate between IgG and IgM antibodies

Compares favorably to FTA test but slightly less sensitive in untreated early primary syphilis

Cannot be tested with CSF

Do not use assay for blood donor screening or associated re-entry protocols

 
Treponema pallidum Antibody (FTA-ABS), Serum, IgG by IFA with Reflex to Treponema pallidum Antibody by TP-PA 0050477
Method: Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Particle Agglutination 

Confirm reactive screening nontreponemal test in suspected syphilis

Confirm inconclusive results from Treponema pallidum (VDRL)

Resolve discrepancies between laboratory results and clinical impressions

FTA tests for syphilis may be false positive in autoimmune disease, leprosy, febrile illnesses, advanced age, Lyme disease and endemic treponematoses

May be helpful in late neurosyphilis when RPR is negative but high clinical suspicion for disease

FTA antibody testing will usually remain reactive despite adequate therapy; do not use to monitor therapy

Do not use assay for blood donor screening or associated re-entry protocols

 
Treponema pallidum Antibody, IgM by ELISA 0050921
Method: Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Discriminate maternally derived IgG antibodies that cross placenta from IgM antibodies that indicate active infection in the newborn

Confirm congenital syphilis

Highly specific (100%) and sensitive (91%) test

Congenital syphilis – sensitivity is ~80%; therefore, negative IgM does not rule out congenital syphilis

 
Treponema pallidum Antibody, IgG by Immunoblot 2003095
Method: Qualitative Immunoblot

Detect IgG antibodies against T. pallidum; useful as supplemental treponemal-based assay in cases where FTA-Abs results are inconclusive

Do not use to determine relapse or reinfection of syphilis because of the persistence of reactivity, likely for life

Repeat testing in 2-4 weeks is recommended if results are equivocal

Additional Tests Available
 
Click the plus sign to expand the table of additional tests.
Test Name and NumberComments
Treponema pallidum (VDRL), Cerebrospinal Fluid with Reflex to Titer 0050206
Method: Semi-Quantitative Flocculation
Treponema pallidum (Rapid Plasma Reagin) with Reflex to Titer, FTA-ABS and TP-PA 0050011
Method: Semi-Quantitative Charcoal Agglutination/Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Particle Agglutination

Follow treatment response

Satisfactory first-line test but higher rate of false positives

Panel is for clients in states requiring automatic confirmation via treponemal test for all reactive RPR tests

Treponema pallidum (Rapid Plasma Reagin) with Reflex to Titer and TP-PA Confirmation 0050478
Method: Semi-Quantitative Charcoal Agglutination/Semi-Quantitative Particle Agglutination
Treponema pallidum Antibody, IgG by ELISA 0050920
Method: Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Treponema pallidum Antibody, IgG by IFA (CSF) 0055273
Method: Semi-Quantitative Indirect Fluorescent Antibody
Treponema pallidum Antibody Panel (FTA-ABS) IgG & IgM 0093067
Method: Qualitative Immunofluorescence Assay
(Indirect Fluorescent Antibody)

Diagnostic Algorithm